Navigation Links
FDA Approves New Treatment for Chronic Hepatitis B

The Food and Drug Administration (FDA) announced the approval of Baraclude (entecavir) tablets and oral solution for the treatment of chronic hepatitis B in adults. Chronic hepatitis B is a serious disease caused by the hepatitis B virus (HBV) that attacks the liver. The virus can cause lifelong infection, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death. According to the Centers for Disease Control and Prevention, approximately 1.25 million Americans are chronically infected with the HBV virus.

Baraclude slows the progression of chronic hepatitis B by interfering with viral reproduction.

FDA based its approval of Baraclude on the results of three studies in which Baraclude was compared to another anti-viral drug, lamivudine.

In all three clinical studies, patients treated with Baraclude showed significant improvement in the liver inflammation caused by HBV and an improvement in the degree of liver fibrosis (scarring). In addition, a higher percentage of patients treated with Baraclude showed significant improvement compared to lamivudine.

The major adverse events associated with the use of Baraclude were of the type typically seen with HBV therapy. They include severe, acute exacerbation of hepatitis B after discontinuation of Baraclude, headache, abdominal pain, diarrhea, fatigue, and dizziness. The labeling for Baraclude states that patients who discontinue Baraclude should be monitored at repeated intervals over a period of time for liver function.

Baraclude's sponsor, Bristol-Myers Squibb Company of Wallingford, Conn., has committed to conducting a large post-marketing study of Baraclude (entecavir) to evaluate the risks of cancers and liver related complications.


'"/>

Source:U.S. FDA


Page: 1

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. FDA Approves New Drug to Treat Type I and Type II Diabetes
3. Discovery Could Lead To Novel Approaches In HIV Treatment
4. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Effective Cancer Treatments Follow The Clock
7. Protein Discovery Could Unlock The Secret To Better TB Treatment
8. Natural Killers Could Lead to New Hepatitis Treatments
9. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
10. Drug Offers Alternative to Surgical Treatment After Miscarriage
11. Treatments have same target, different responses for lung cancer patients with genetic mutation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions ... Police Department in Missouri solved ... plate reader (LPR) data from Vigilant Solutions. ... case in which the victim was walking out of a convenience store and ... space next to his vehicle, striking his vehicle and ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... SAN DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: ... year ended December 31, 2015. --> ... reported a net loss of $29.3 million, or $0.34 loss per ... loss per share for the same period in 2014. For the ... of $88.9 million, or $1.05 loss per share, as compared to ...
(Date:2/11/2016)... Feb. 11, 2016  Wellcentive today announced it ... Portland, Oregon -based community care organization (CCO) ... health analytics, quality reporting and care management solutions ... its team of quality managers, analysts and care ... provider groups serving FamilyCare members. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... 150 years, continues today to pursue the highest level of accuracy and quality ... the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough enough ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
Breaking Biology Technology: